The Tumultuous Path of BioNTech: From Vaccine Triumphs to Pioneering Cancer Therapies
BioNTech is transitioning from COVID-19 vaccines to focusing on cancer therapies using mRNA platforms. The company reported a significant earnings decline in 2024, with profits falling but exceeding market expectations.…